Methicillin-resistant Staphylococcus aureus (MRSA) (MRSA)

Methicillin-resistant Staphylococcus aureus (MRSA) is a Gram-positive bacterium that has developed resistance to most beta-lactam antibiotics, including methicillin, oxacillin, and cephalosporins, primarily through the acquisition of the mecA gene. This gene encodes Penicillin-Binding Protein 2a (PBP2a), which possesses a low affinity for beta-lactams, allowing cell wall synthesis to continue despite the presence of these drugs (StatPearls, 2023). The concept of 'Combination pharmacodynamic interaction' in the context of MRSA refers to the synergistic or additive effects achieved when two or more antimicrobial agents are used simultaneously to overcome resistance or enhance bactericidal activity (Journal of Antimicrobial Chemotherapy, 2021). For example, the combination of daptomycin and a beta-lactam like ceftaroline is often used to treat refractory MRSA bacteremia, as the beta-lactam can induce 'see-saw' effects that increase daptomycin binding to the bacterial membrane (Clinical Infectious Diseases, 2019). These interactions are vital for managing complex infections where monotherapy is insufficient or where the prevention of further resistance is a priority.

Other names

MRSAMethicillin-resistant S. aureusOxacillin-resistant Staphylococcus aureusORSAMultidrug-resistant Staphylococcus aureus

Drugs targeting MRSA utilize diverse mechanisms: glycopeptides like vancomycin inhibit cell wall synthesis by binding to D-Ala-D-Ala; lipopeptides like daptomycin depolarize the cell membrane; oxazolidinones like linezolid inhibit protein synthesis at the 50S ribosome; and certain cephalosporins like ceftaroline bind to the resistant PBP2a. Combination pharmacodynamic interactions involve the synergistic use of these mechanisms, such as using beta-lactams to enhance the binding of daptomycin or using rifampin to penetrate biofilms (PubMed, 2021; StatPearls, 2023).